Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Anandkumar Raichurkar"'
Autor:
Manoranjan Panda, Anandkumar Raichurkar, Neela Dinesh, Vinayak Hosagrahara, Naveen Kumar, K.R. Prabhakar, Suresh Rudrapatna, Gayathri Balakrishnan, Amit K. Gupta, Vasan K. Sambandamurthy, Karthikeyan Kandaswamy, Stefan Kavanagh, Ramanatha Saralaya, Lalit kumar Jena, Shridhar Narayanan, Suresh Solapure, Robert Nanduri, V. Balasubramanian, Meenakshi Mallya, Ashwini Narayan, Sowmya Bharath, Vijender Panduga, Vikas Shinde, Jitendar Reddy, Khisi Mdluili, Christopher B. Cooper, Parvinder Kaur, Shahul Hameed P, Sreevalli Sharma, Supreeth Guptha, Kakoli Mukherjee, Sudha Ravishankar, Radha Shandil, Pravin Iyer, Shankar D. Markad, Vasanthi Ramachandran, Takahiro Yano, Jyothi Bhat, Harvey Rubin, Subramanyam J. Tantry
Publikováno v:
MedChemComm. 7:1022-1032
The success of bedaquiline as an anti-tubercular agent for the treatment of multidrug-resistant tuberculosis has validated the ATP synthesis pathway and in particular ATP synthase as an attractive target. However, limitations associated with its use
Autor:
Parvinder Kaur, Shankar D. Markad, B. K. Kishore Reddy, Manoranjan Panda, Murugan Chinnapattu, Radha Nandishaiah, Anandkumar Raichurkar, Pravin Iyer
Publikováno v:
Medicinal Chemistry Research. 24:2986-2992
The key to shortening tuberculosis (TB) drug regimen lies in eliminating the reservoir of non-replicating persistent (NRP) Mycobacterium tuberculosis (Mtb). Pyrazinamide (PZA) is the only known drug used as part of a combination therapy that is belie
Autor:
Rajesh Kalkhambkar, Bheemarao G. Ugarkar, Jon Read, Martin Vogtherr, Beena Paul, Swati Prasad, Adrian Liam Gill, Shantika Bhat, Helen H.J. McMiken, Maruti Naik, Jyothi Bhat, Julie A. Tucker, Kevin J. Embrey, Begur Vasanthkumar Varun, Balachandra Bandodkar, Rani Menon, Syeed Hussein, Janani Venkatraman, Kannan Murugan, Harini Iyer, Anandkumar Raichurkar, Manoranjan Panda
Publikováno v:
Journal of Medicinal Chemistry. 58:753-766
M. tuberculosis thymidylate kinase (Mtb TMK) has been shown in vitro to be an essential enzyme in DNA synthesis. In order to identify novel leads for Mtb TMK, we performed a high throughput biochemical screen and an NMR based fragment screen through
Autor:
Thierry Kogej, Chris L. Waller, Darren V. S. Green, Anandkumar Raichurkar, George Papadatos, Andreas Verras, Julie Clark, Peter Gedeck, Jeremy N. Burrows, R. Kiplin Guy, Anang A. Shelat, Manoranjan Panda
Publikováno v:
Journal of chemical information and modeling. 57(3)
The development of new antimalarial therapies is essential, and lowering the barrier of entry for the screening and discovery of new lead compound classes can spur drug development at organizations that may not have large compound screening libraries
Autor:
Jitendar Reddy, Parvinder Kaur, Dharmarajan Sriram, Anandkumar Raichurkar, Sreevalli Sharma, Radha Nandishaiah, Sreenivasaiah Menasinakai, Shahul Hameed P, Vasan K. Sambandamurthy, Vijender Panduga, Prashanti Madhavapeddi
Publikováno v:
ACS Medicinal Chemistry Letters. 5:820-825
Type II topoisomerases are well conserved across the bacterial species, and inhibition of DNA gyrase by fluoroquinolones has provided an attractive option for treatment of tuberculosis (TB). However, the emergence of fluoroquinolone-resistant strains
Autor:
V. K. Ramya, Vijender Panduga, Gajanan Shanbhag, Michelle Coulson, Sowmya Bharath, Vaishali Humnabadkar, Prashanti Madhavapeddi, Vasan K. Sambandamurthy, Disha Awasthy, Jim Werngren, Praveena Manjrekar, Chandan Narayan, Vijayashree Achar, Mahesh Kumar Kn, Sunita M. de Sousa, Jitendar Reddy, C. N. Naveen Kumar, Kakoli Mukherjee, Sreenivasaiah Menasinakai, Ugarkar Bheemarao, Samit Ganguly, Umender Sharma, David Waterson, Vikas Patil, Sven Hoffner, Radha Nandishaiah, Sreevalli Sharma, Shahul Hameed P, Uma Arora, Anandkumar Raichurkar, Suresh Solapure, Parvinder Kaur, Jayashree Puttur, Vikas Shinde, Murugan Chinnapattu, Suresh Rudrapatana, Sheshagiri Gaonkar, Anirban Ghosh
Publikováno v:
Journal of Medicinal Chemistry. 57:4889-4905
DNA gyrase is a clinically validated target for developing drugs against Mycobacterium tuberculosis (Mtb). Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the prevalence of pre-existing resistance to FQs is likely to restric
Autor:
Parvinder Kaur, Anisha Ambady, Sreevalli Sharma, Vinayak Hosagrahara, Ashwini Narayan, Vasanthi Ramachandran, Suresh Rudrapatna, Supreeth Guptha, Pravin S. Shirude, Vasan K. Sambandamurthy, Jyothi Mahadevaswamy, Ramachandran Sreekanth A, Kavitha Nagalapur, Anandkumar Raichurkar, Naina Hegde, Manoranjan Panda, Vaishali Humnabadkar
Publikováno v:
Journal of Medicinal Chemistry. 57:4761-4771
A novel pyrazolopyridone class of inhibitors was identified from whole cell screening against Mycobacterium tuberculosis (Mtb). The series exhibits excellent bactericidality in vitro, resulting in a 4 log reduction in colony forming units following c
Autor:
P. Ann Boriack-Sjodin, B. K. Kishore Reddy, Ramesh R. Kale, Vijaykamal Ahuja, Sunita M. de Sousa, Krishnan Malolanarasimhan, Sheshagiri Gaonkar, Anandkumar Raichurkar, Sreenivasaiah Menasinakai, Halesha D. Basavarajappa, Prashanti Madhavapeddi, M. R. Manjunatha, Shahul Hameed, David Waterson, Radha Nandishaiah, Vasan K. Sambandamurthy, C. N. Naveen Kumar, Derek Ogg, Vikas Shinde, Vaishali Humnabadkar, Krishna Koushik, Sreevalli Sharma, K. N. Mahesh Kumar, Sandeep R. Ghorpade, Kale Manoj Ganpat, Samit Ganguly, Lalit kumar Jena
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:870-879
Scaffold hopping from the thiazolopyridine ureas led to thiazolopyridone ureas with potent antitubercular activity acting through inhibition of DNA GyrB ATPase activity. Structural diversity was introduced, by extension of substituents from the thiaz
Autor:
Suresh Rudrapatana, Anandkumar Raichurkar, Vasan K. Sambandamurthy, Vikas Shinde, Sreevalli Sharma, Suresh Solapure, Prashanti Madhavapeddi, Gajanan Shanbhag, Dharmarajan Sriram, Vikas Patil, Radha Nandishaiah, Shahul Hameed P, Jayashree Puttur, Murugan Chinnapattu, C. N. Naveen Kumar, Praveena Manjrekar
Structure–activity relationship (SAR) exploration on the left-hand side (LHS) of a novel class of bacterial topoisomerase inhibitors led to a significant improvement in the selectivity against hERG cardiac channel binding with concomitant potent an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac968c632a8bdcdbbc3e92c95d376ab6
https://europepmc.org/articles/PMC4499837/
https://europepmc.org/articles/PMC4499837/
Autor:
Shridhar Narayanan, Laura M. Sanz, Sreenivasaiah Menasinakai, Kevin Hickling, Abhishek Srivastava, Sapna Morayya, Anandkumar Raichurkar, Vikas Patil, Stefan Kavanagh, María Belén Jiménez-Díaz, Ramanatha Saralaya, Vijender Panduga, Gajanan Shanbag, Eknath V. Bellale, Lyn Rosenbrier-Ribeiro, K.R. Prabhakar, Anisha Ambady, David Waterson, Nikhil Rautela, Kannan Murugan, Pavithra Viswanath, Peter Warner, Pamela Magistrado, Pravin Iyer, Dyann F. Wirth, Jayashree Puttur, Krishna Koushik, Sowmya Bharath, Nilanjana Roy Choudhury, Philipp P. Henrich, Olivia Coburn-Flynn, Suresh Solapure, Radha Nandishaiah, Balachandra Bandodkar, Kakoli Mukherjee, María Santos Martínez, Suresh Rudrapatna, David A. Fidock, Shahul Hameed P, Vinayak Hosagrahara, Monalisa Chatterji, Vasan K. Sambandamurthy, V. Balasubramanian, Sudhir Landge, Jitendar Reddy, Robert E. McLaughlin, Amanda K. Lukens, Adam Jeston Dudley, Disha Awasthy
Publikováno v:
Nature Communications
The widespread emergence of Plasmodium falciparum (Pf) strains resistant to frontline agents has fuelled the search for fast-acting agents with novel mechanism of action. Here, we report the discovery and optimization of novel antimalarial compounds,